Genmab A/S (GNMSF)
USD 200.0
(0.96%)
USD 200.0
(0.96%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 16.47 Billion DKK | 12.87% |
| 2022 | 14.59 Billion DKK | 72.07% |
| 2021 | 8.48 Billion DKK | -16.11% |
| 2020 | 10.11 Billion DKK | 88.43% |
| 2019 | 5.36 Billion DKK | 77.38% |
| 2018 | 3.02 Billion DKK | 27.89% |
| 2017 | 2.36 Billion DKK | 30.25% |
| 2016 | 1.81 Billion DKK | 60.29% |
| 2015 | 1.13 Billion DKK | 33.24% |
| 2014 | 850.38 Million DKK | 28.15% |
| 2013 | 663.57 Million DKK | 36.92% |
| 2012 | 484.63 Million DKK | 38.1% |
| 2011 | 350.93 Million DKK | -39.71% |
| 2010 | 582.07 Million DKK | -0.68% |
| 2009 | 586.07 Million DKK | -21.34% |
| 2008 | 745.11 Million DKK | 40.71% |
| 2007 | 529.53 Million DKK | 290.67% |
| 2006 | 135.54 Million DKK | 37.6% |
| 2005 | 98.5 Million DKK | 2301.98% |
| 2004 | 4.1 Million DKK | -94.0% |
| 2003 | 68.32 Million DKK | 0.0% |
| 2002 | - DKK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 5.4 Billion DKK | 30.39% |
| 2024 Q1 | 4.14 Billion DKK | -11.44% |
| 2023 Q3 | 4.74 Billion DKK | 13.01% |
| 2023 Q1 | 2.85 Billion DKK | -45.4% |
| 2023 FY | 16.47 Billion DKK | 12.87% |
| 2023 Q2 | 4.19 Billion DKK | 47.09% |
| 2023 Q4 | 4.67 Billion DKK | -1.39% |
| 2022 FY | 14.59 Billion DKK | 72.07% |
| 2022 Q2 | 3.16 Billion DKK | 49.22% |
| 2022 Q1 | 2.11 Billion DKK | -19.09% |
| 2022 Q3 | 4.08 Billion DKK | 29.25% |
| 2022 Q4 | 5.22 Billion DKK | 27.89% |
| 2021 FY | 8.48 Billion DKK | -16.11% |
| 2021 Q4 | 2.61 Billion DKK | 13.38% |
| 2021 Q3 | 2.31 Billion DKK | 17.14% |
| 2021 Q2 | 1.97 Billion DKK | 24.73% |
| 2021 Q1 | 1.58 Billion DKK | -22.65% |
| 2020 Q3 | 1.72 Billion DKK | -68.37% |
| 2020 FY | 10.11 Billion DKK | 88.43% |
| 2020 Q4 | 2.04 Billion DKK | 18.56% |
| 2020 Q2 | 5.45 Billion DKK | 511.1% |
| 2020 Q1 | 892 Million DKK | -69.88% |
| 2019 Q3 | 1.03 Billion DKK | 34.36% |
| 2019 Q2 | 773.91 Million DKK | 30.95% |
| 2019 Q1 | 591 Million DKK | -52.18% |
| 2019 Q4 | 2.96 Billion DKK | 184.78% |
| 2019 FY | 5.36 Billion DKK | 77.38% |
| 2018 Q2 | 509.67 Million DKK | -25.16% |
| 2018 Q1 | 681.01 Million DKK | -33.09% |
| 2018 FY | 3.02 Billion DKK | 27.89% |
| 2018 Q4 | 1.23 Billion DKK | 106.46% |
| 2018 Q3 | 598.59 Million DKK | 17.45% |
| 2017 FY | 2.36 Billion DKK | 30.25% |
| 2017 Q4 | 1.01 Billion DKK | 214.69% |
| 2017 Q2 | 773.34 Million DKK | 208.38% |
| 2017 Q3 | 323.44 Million DKK | -58.18% |
| 2017 Q1 | 250.77 Million DKK | -72.96% |
| 2016 Q3 | 364.66 Million DKK | 3.06% |
| 2016 FY | 1.81 Billion DKK | 60.29% |
| 2016 Q4 | 927.46 Million DKK | 154.33% |
| 2016 Q1 | 170.17 Million DKK | -70.39% |
| 2016 Q2 | 353.82 Million DKK | 107.92% |
| 2015 Q1 | 106.77 Million DKK | -50.52% |
| 2015 Q3 | 277.76 Million DKK | 59.78% |
| 2015 Q2 | 173.84 Million DKK | 62.81% |
| 2015 Q4 | 574.65 Million DKK | 106.89% |
| 2015 FY | 1.13 Billion DKK | 33.24% |
| 2014 Q3 | 271.52 Million DKK | 134.09% |
| 2014 FY | 850.38 Million DKK | 28.15% |
| 2014 Q4 | 215.8 Million DKK | -20.52% |
| 2014 Q2 | 115.98 Million DKK | -53.06% |
| 2014 Q1 | 247.07 Million DKK | 14.36% |
| 2013 Q3 | 149.66 Million DKK | 8.38% |
| 2013 FY | 663.57 Million DKK | 36.92% |
| 2013 Q2 | 138.09 Million DKK | -13.57% |
| 2013 Q1 | 159.77 Million DKK | -2.04% |
| 2013 Q4 | 216.04 Million DKK | 44.35% |
| 2012 Q1 | 94.01 Million DKK | 1.01% |
| 2012 Q4 | 163.1 Million DKK | 40.76% |
| 2012 FY | 484.63 Million DKK | 38.1% |
| 2012 Q2 | 111.64 Million DKK | 18.76% |
| 2012 Q3 | 115.87 Million DKK | 3.79% |
| 2011 Q1 | 83.12 Million DKK | -8.81% |
| 2011 Q3 | 90.86 Million DKK | 8.33% |
| 2011 Q2 | 83.87 Million DKK | 0.91% |
| 2011 FY | 350.93 Million DKK | -39.71% |
| 2011 Q4 | 93.06 Million DKK | 2.42% |
| 2010 Q4 | 91.15 Million DKK | -57.52% |
| 2010 Q2 | 169.8 Million DKK | 59.41% |
| 2010 Q1 | 106.52 Million DKK | -44.78% |
| 2010 FY | 582.07 Million DKK | -0.68% |
| 2010 Q3 | 214.59 Million DKK | 26.38% |
| 2009 Q1 | 249.98 Million DKK | 0.0% |
| 2009 FY | 586.07 Million DKK | -21.34% |
| 2009 Q3 | 69.02 Million DKK | -6.94% |
| 2009 Q4 | 192.89 Million DKK | 179.45% |
| 2009 Q2 | 74.17 Million DKK | -70.33% |
| 2008 FY | 745.11 Million DKK | 40.71% |
| 2007 FY | 529.53 Million DKK | 290.67% |
| 2006 FY | 135.54 Million DKK | 37.6% |
| 2005 FY | 98.5 Million DKK | 2301.98% |
| 2004 FY | 4.1 Million DKK | -94.0% |
| 2003 FY | 68.32 Million DKK | 0.0% |
| 2002 FY | - DKK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 18.21 Million USD | -90327.05% |
| BioStem Technologies, Inc. | 16.68 Million USD | -98632.994% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | -13298.526% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -852591.511% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -6963883.767% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -2501646.393% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -21755221.959% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| CSL Limited | 14.69 Billion USD | -12.144% |
| Capstone Therapeutics Corp. | 48.35 Million USD | -33969.57% |
| Adynxx, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -104344.304% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -93490621.298% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 21.47 Million USD | -76601.741% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -25063799.708% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Mesoblast Limited | 5.9 Million USD | -279025.72% |
| Marizyme, Inc. | 645.81 Thousand USD | -2550805.065% |
| Genus plc | 668.8 Million USD | -2363.218% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 245.31 Million USD | -6615.42% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -16641312.611% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -4016332.411% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -21461319.21% |
| IMV Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -41687232.355% |
| MultiCell Technologies, Inc. | 49.32 USD | -33402270784.023% |
| ONE Bio Corp. | 52.29 Million USD | -31401.331% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 49.72 Million USD | -33032.881% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -33689061.554% |
| Q BioMed Inc. | 284.35 Thousand USD | -5793423.52% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | -55561.047% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | -11253.578% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -2953764.912% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -23534185.714% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 999.00 USD | -1649048949.049% |
| Enzolytics Inc. | 52.79 Thousand USD | -31203021.449% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -2707101.841% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | -1243.373% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -11746737.609% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -2668255.513% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 839.52 Million USD | -1862.291% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -1651054.726% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -6963883.767% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.36 Million USD | -1203260.117% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -3477408.285% |
| SYBLEU INC | 11.69 Thousand USD | -140851473.187% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -211403.402% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -126722976.923% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -41670360.869% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -494614.715% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -247071.793% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -1585463.041% |
| Gelesis Holdings, Inc. | 25.76 Million USD | -63834.49% |
| CSL Limited | 14.8 Billion USD | -11.311% |
| Cellectis S.A. | 755 Thousand USD | -2181886.755% |